Adam Olszewski MD (@lymphomatic) header
Adam Olszewski MD (@lymphomatic) profile picture

Adam Olszewski MD

@lymphomatic

Lymphoma oncologist at Brown University / Rhode Island Hospital

 Brown University
vivo.brown.edu/display/aolszews
Joined November 2014
  • Tweets120
  • Following130
  • Followers719
15Media
Photo by Adam Olszewski MD (@lymphomatic)Photo by Adam Olszewski MD (@lymphomatic)Photo by Adam Olszewski MD (@lymphomatic)Photo by Adam Olszewski MD (@lymphomatic)Photo by Adam Olszewski MD (@lymphomatic)Photo by Adam Olszewski MD (@lymphomatic)Photo by Adam Olszewski MD (@lymphomatic)Photo by Adam Olszewski MD (@lymphomatic)Photo by Adam Olszewski MD (@lymphomatic)Photo by Adam Olszewski MD (@lymphomatic)
New: Final results from the phase 3 HOVON/SAKK trial, comparing R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma thelancet.com/journals/lanha…
Image from The Lancet Haematology (@TheLancetHaem)
39
3
84
25,042
Adam Olszewski MD retweeted
Katharine Lewis (@Dr_KatLewis) profile picture
Katharine Lewis@Dr_KatLewis5 Oct 2023
Delighted to share our work now published on behalf of all co-authors. Our practice has changed- minimal use of HD-MTX in CNS prophylaxis in aNHL. Thank you so much to all international collaborators! ascopubs.org/doi/10.1200/JCO…
High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma

PURPOSECNS progression or relapse is an uncommon but devastating complication of aggressive B-cell lymphoma. There is no consensus regarding the optimal approach to CNS prophylaxis. This study was...

ascopubs.org
7
31
3
108
14,532
🙌TY to all collaborators (@sairah__ahmed, @LNastoupilMD, @uroosaibrahim, @NEpperla, @tvoorheesmd, @lymphomatic etc) & @RutgersCancer fellow Dr McKenna on this #RWE of #CART for rel/ref SOT-PTLD. We describe immunosupression, toxicity & outcomes. @BrJHaem onlinelibrary.wiley.com/doi/…
Real‐world evidence of the safety and survival with CD19 CAR‐T cell therapy for relapsed/refractory...

Real‐world evidence of the safety and survival with CD19 CAR‐T cell therapy for relapsed/refractory...

The use of CD19 chimeric antigen receptor T-cell (CAR-T) therapy for relapsed/refractory solid organ transplantation (SOT)-related post-transplant lymphoproliferative disorder (PTLD) is not well...

onlinelibrary.wiley.com
11
1
26
3,520
Adam Olszewski MD retweeted
Liz Brem, MD (@DrLizBrem) profile picture
Liz Brem, MD@DrLizBrem22 Mar 2023
East coast friends! @JohnPLeonardMD gave @lymphomatic and I the challenge of debating the utility of CNS prophylaxis in DLBCL. Come learn and watch us duke it out on 04/13 in NYC! Register now: okt.to/7oIirY @GreatDebatesCME #bloodcancer #HematologicMalignancies
3
5
1
24
4,380
Adam Olszewski MD retweeted
Mengyang Di, MD PhD (@DiMengyang) profile picture
Mengyang Di, MD PhD@DiMengyang23 Mar 2023
Check out our study on function, treatment, and outcomes in nursing home patients w/ DLBCL- a population very challenging to manage! Glad to see this published. This concludes a series of projects on older pts w/ aggressive lymphoma that are very close to my heart! @lymphomatic
JAGS (@AGSJournal) profile pictureJAGS@AGSJournal20 Mar 2023
Functional status and therapy for older adults with diffuse large B-cell lymphoma in nursing homes: A population-based study. agsjournals.onlinelibrary.wi… #geriatrics
Image from JAGS (@AGSJournal)
2
5
12
4,256
Editorial: The demise of Roe v Wade: a hematologist’s perspective loom.ly/MkH8V3g
The demise of Roe v Wade: a hematologist’s perspective

The demise of Roe v Wade: a hematologist’s perspective

The impact of the Dobbs v Jackson Women's Health Organization decision by the US Supreme Court, removing federal protection of abortion rights, has importa

ashpublications.org
13
1
25
Defining and treating high-grade B-cell #lymphoma, NOS ashpublications.org/blood/ar… TY to @BrownMedicine @lymphomatic & @BrownUniversity Dr Kurt collab on this review. 2 new classifications out since this was pre-published ~1 year ago but most content still valid/relevant! #lymsm
Defining and treating high-grade B-cell lymphoma, NOS

Defining and treating high-grade B-cell lymphoma, NOS

Edited by Associate Editor Laurie Sehn, this 3-part Review Series covers rare, aggressive B-cell lymphomas. First, Olszewski et al discuss a recently-desig

ashpublications.org
3
12
2
24
#COVID19 booster vaccination leads to seroconversion in over 1/2 of patients w/ hematologic malignancies who had undetectable antibodies to the initial vaccine series. The risk of death appears highest in those with undetectable antibodies. acsjournals.onlinelibrary.wi… @OncoAlert
Image from ACS Journal Cancer (@JournalCancer)
1
2
10
Adam Olszewski MD retweeted
BioAscend (@BioAscend) profile picture
BioAscend
@BioAscend10 Mar 2022
Register at bit.ly/3GWO3nN to hear the latest research & info on aggressive #lymphoma from Dr. David Scott, @lymphomatic, Dr. Neha Mehta-Shah & Dr. Dan Landsburg at #IUCLS2022! Join us live in Chicago April 29-30! @UChicagoCME
Image from BioAscend (@BioAscend)
2
3
Defining and Treating High-grade B-cell #lymphoma, NOS | @BloodJournal @ASH_hematology ashpublications.org/blood/ar… Happy to publish this review w/ @RIHospital @BrownUCancer @lymphomatic & Dr Kurt on the challenging topic/entity of HGBL-NOS (1st pic below is correct Fig 1). #lymsm
Image from Andrew M. Evens, DO, MBA, MSc (@DrAEvens)
Image from Andrew M. Evens, DO, MBA, MSc (@DrAEvens)
3
42
95
The future of CLL therapy has arrived: our ph2 AVO trial in 1L CLL from @DanaFarber and @BIDMChealth with support from @AstraZeneca and @genentech is now online @TheLancetOncol authors.elsevier.com/a/1dlF4…
8
16
1
89
Adam Olszewski MD retweeted
Tom Ollila (@OllilaTom) profile picture
Tom Ollila@OllilaTom11 Aug 2021
Honored Jama Onc has published our work. Please get yourself vaccinated for those in whom it does not work. Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease ja.ma/3iCBPXS via @JAMAOnc part of @JAMANetwork
1
9
3
16
Kudos to @BrownUniversity @RIHospital Adam & Adam (@lymphomatic) on detailed #RWE analysis of CNS involvement in Burkitt #lymphoma. Several interesting nuggets of info gleaned (incidence, characteristics, outcomes, etc). Early View | Haematologica haematologica.org/article/vi… #lymsm
Image from Andrew M. Evens, DO, MBA, MSc (@DrAEvens)
Image from Andrew M. Evens, DO, MBA, MSc (@DrAEvens)
Image from Andrew M. Evens, DO, MBA, MSc (@DrAEvens)
Image from Andrew M. Evens, DO, MBA, MSc (@DrAEvens)
9
17
Thanks much 👏 @chanyooncheah (and @CwynKate, @graham74GC, Dr El-Galaly & many others) for collaborating on this work! It was great to combine International forces to analyze 1,000+ Burkitt #lymphoma patients and generate/validate this prognostication index (aka #BLIPI). #lymsm
Chan Cheah (@chanyooncheah) profile pictureChan Cheah@chanyooncheah28 Jan 2021
Congrats @lymphomatic @DrAEvens et al on leading this collaboration @JCO_ASCO Burkitt Lymphoma International Prognostic Index (aka BLIPI) #lymSM - age≥40, ECOG≥2, LDH≥3xULN = 1 point - 0, 1, 2+ factors = 3-year PFS 92, 72 ,53% ascopubs.org/doi/abs/10.1200…
Burkitt Lymphoma International Prognostic Index

Burkitt Lymphoma International Prognostic Index

PURPOSEBurkitt lymphoma (BL) has unique biology and clinical course but lacks a standardized prognostic model. We developed and validated a novel prognostic index specific for BL to aid risk strati...

ascopubs.org
2
5
2
19
Our study evaluating prognostic factors driving Burkitt lymphoma outcome is out in this issue of @BloodJournal Thank you to all investigators for their contribution. @DrAEvens @lymphomatic ashpublications.org/blood/ar…
Image from Juan P. Alderuccio (@JuanAlderuccio)
5
7
3
74
Adam Olszewski MD retweeted
Oncology Tube (@oncologytube) profile picture
Oncology Tube
@oncologytube22 Dec 2020
The Burkitt Lymphoma International Prognostic Index Andrew M. Evens, DO, MSc @DrAEvens @RutgersCancer #ASH20 #Lymphoma #Cancer #Research Link To Full Video: oncologytube.com/video/39713…
2
1
8
Single-agent mosunetuzumab in older/unfit patients with previously untreated DLBCL. Promising results for this bispecific antibody therapy in this older population (median age of 82), both in terms of safety and activity #ASH20 #lymphoma
Image from The Lancet Haematology (@TheLancetHaem)
Image from The Lancet Haematology (@TheLancetHaem)
Image from The Lancet Haematology (@TheLancetHaem)
Image from The Lancet Haematology (@TheLancetHaem)
5
13
Adam Olszewski MD retweeted
Graham Collins (@graham74GC) profile picture
Graham Collins@graham74GC4 Nov 2020
Olszewski et al - Burkitt lymphoma IPI - 633 derivation (US); 437 validation cohorts (Eur) - Poor prog: Age 40+, LDH 3x ULN, PS 2+, CNS disease - low / intermed / high risk: 3y OS: 99%, 85%, 64% - Can we de-esc Rx in low risk? Fantastic US/UK/EU partnership #lymsm #ASH20
Image from Graham Collins (@graham74GC)
2
8
3
28
Adam Olszewski MD retweeted
Chan Cheah (@chanyooncheah) profile picture
Chan Cheah@chanyooncheah4 Sep 2020
Ollila et al @lymphomatic provide some elegant work in @BloodJournal MCD subtype (with genomic profile similar to primary CNS lymphoma) associated with CNS relapse in diffuse large B-cell lymphoma ashpublications.org/blood/ar… #lymSM
1
1
6
New work from @lymphomatic in @BloodAdvances shows that #hospice use in blood cancers is assoc/w better EOL care quality: less death in hospital, less ICU or chemo use, and lower costs, regardless of blood cancer type #leusm #lymsm #mmsm #bmtsm ashpublications.org/bloodadv…
5
18
Load more